Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder
- PMID: 21862035
- DOI: 10.1016/j.jpsychires.2011.07.014
Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder
Abstract
Background: To examine the influencing factors and predictors of early improvement in schizophrenia patients.
Methods: 370 patients suffering from a schizophrenia spectrum disorder were examined within a naturalistic multicenter study. Early improvement was defined as a ≥30% PANSS total score reduction within the first two treatment weeks, response as a ≥50% improvement of the PANSS total score from admission to discharge and remission according to the consensus remission criteria. Baseline and course-related variables such as positive, negative and depressive symptoms, side effects, functioning and subjective well-being were examined regarding their explanatory value for early improvement.
Results: 46% of the patients were identified to be early improvers. Of these, 77% became treatment responder at discharge and 74% achieved the consensus remission criteria. Amongst others, early improvers were significantly more often first-episode patients (p = 0.009), with a significantly shorter duration of current episode (p = 0.024) and a shorter duration of the illness (p = 0.0094). A higher PANSS positive subscore (p = 0.0089), a higher score in the Strauss-Carpenter-Prognostic Scale (SCPS) (p < 0.0001), less extrapyramidal side effects (p = 0.0004) at admission and the development of less extrapyramidal side effects within the first two treatment weeks (p = 0.0013) as well as a duration of current episode of ≤6 months (p = 0.0373) were identified to be significant predictors of early improvement.
Conclusion: Early improvement is associated with less illness chronicity and seems to be independent of the type of antipsychotic and the antipsychotic dosage applied. The SCPS was found to be a valuable tool to detect early improvers already at the initiation of antipsychotic treatment.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
One-year functional outcomes of naturalistically treated patients with schizophrenia.Psychiatry Res. 2012 Aug 15;198(3):378-85. doi: 10.1016/j.psychres.2011.12.047. Epub 2012 Mar 14. Psychiatry Res. 2012. PMID: 22421065
-
Prediction of symptom remission in schizophrenia during inpatient treatment.World J Biol Psychiatry. 2009;10(4 Pt 2):426-34. doi: 10.1080/15622970701541054. World J Biol Psychiatry. 2009. PMID: 17853260
-
Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.J Clin Psychiatry. 2010 Mar;71(3):280-6. doi: 10.4088/JCP.08m04250yel. Epub 2009 Nov 3. J Clin Psychiatry. 2010. PMID: 19895779 Clinical Trial.
-
Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?World J Biol Psychiatry. 2010 Aug;11(5):729-38. doi: 10.3109/15622971003690289. World J Biol Psychiatry. 2010. PMID: 20380620
-
Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance.Eur Neuropsychopharmacol. 2015 Oct;25(10):1578-85. doi: 10.1016/j.euroneuro.2015.06.008. Epub 2015 Jun 20. Eur Neuropsychopharmacol. 2015. PMID: 26145487 Review.
Cited by
-
Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.Eur Child Adolesc Psychiatry. 2015 Dec;24(12):1485-96. doi: 10.1007/s00787-015-0725-1. Epub 2015 Jun 2. Eur Child Adolesc Psychiatry. 2015. PMID: 26032132 Clinical Trial.
-
The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population.BMC Psychiatry. 2015 Jan 22;15:1. doi: 10.1186/s12888-014-0378-5. BMC Psychiatry. 2015. PMID: 25609320 Free PMC article.
-
Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.Schizophr Bull. 2015 Sep;41(5):1143-52. doi: 10.1093/schbul/sbu220. Epub 2015 Feb 18. Schizophr Bull. 2015. PMID: 25698711 Free PMC article.
-
Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People's Republic of China.Neuropsychiatr Dis Treat. 2014 May 16;10:869-78. doi: 10.2147/NDT.S59468. eCollection 2014. Neuropsychiatr Dis Treat. 2014. PMID: 24876779 Free PMC article.
-
Psychosocial outcome in patients at clinical high risk of psychosis: a prospective follow-up.Soc Psychiatry Psychiatr Epidemiol. 2013 Feb;48(2):303-11. doi: 10.1007/s00127-012-0545-2. Epub 2012 Jul 15. Soc Psychiatry Psychiatr Epidemiol. 2013. PMID: 22797132
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical